Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters

Gepotidacin is a novel triazaacenaphthylene antibiotic in phase III development. Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate clinical drug–drug interactions (DDIs). We assessed gepotidacin as a DD...

Descripción completa

Detalles Bibliográficos
Autores principales: Barth, Aline, Perry, Caroline R., Shabbir, Shaila, Zamek‐Gliszczynski, Maciej J., Thomas, Sebin, Dumont, Etienne F., Brimhall, Darin B., Nguyen, Dung, Srinivasan, Meenakshi, Swift, Brandon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087077/
https://www.ncbi.nlm.nih.gov/pubmed/36642822
http://dx.doi.org/10.1111/cts.13477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087077/
https://www.ncbi.nlm.nih.gov/pubmed/36642822
http://dx.doi.org/10.1111/cts.13477

Ejemplares similares